Explain
Reading File
Finding Sources
Finding Sources
Finding Sources
Here is a thorough explanation of the case and the P-drug selection exercise:
Exercise 4 — Clinical Case Analysis
The Clinical Scenario
Patient: Suyash Pawar, 30-year-old male, Navi Mumbai
Presenting complaints: High-grade fever with chills and rigors, severe headache, backache
Blood investigations:
- Hb: 10.7 g/dL (low — anaemia)
- RBC: 4 million/cu.mm
- WBC: 9900/cu.mm (slightly elevated — infection)
- Blood smear: Plasmodium falciparum (the most dangerous malaria parasite)
Key history: Completed a full course of chloroquine — but symptoms were NOT relieved.
Diagnosis: Chloroquine-resistant P. falciparum malaria
This is a critical diagnosis. P. falciparum already has high intrinsic resistance rates to chloroquine globally, and this patient's treatment failure confirms it.
What Is a "P-Drug"?
A P-drug (Personal Drug) is a concept from rational pharmacotherapy — the idea that a prescriber maintains a short personal list of well-studied, trusted drugs for common conditions, selected after systematic comparison of all available options. The P-drug is chosen by weighing:
| Criterion | Meaning |
|---|---|
| Efficacy | How effective is the drug against the target condition? |
| Safety | What is the adverse effect profile and risk of toxicity? |
| Suitability | Is it appropriate for this specific patient (age, route, cost, compliance, contraindications)? |
| (Cost) | Affordability and availability |
More "+" signs in the table = better performance on that criterion.
The P-Drug List for Chloroquine-Resistant Malaria
| Drug | Efficacy | Safety | Suitability |
|---|---|---|---|
| Quinine | ++++ | ++ | ++++ |
| Artemisinin / SIP combination | +++++ | +++ | ++++ |
| Atovaquone–Proguanil (Malarone) | ++++ | ++++ | ++++ |
| Artemisinin / Lumefantrine (Coartem) | +++++ | +++ | ++++ |
| IM Artesunate | ++++ | +++++ | +++ |
Drug-by-Drug Explanation
1. Quinine
- One of the oldest antimalarials; acts by concentrating in the parasite's food vacuole and inhibiting haem polymerization.
- Efficacy: Good (++++), but inferior to artemisinin combinations.
- Safety: Only ++ — significant toxicity: cinchonism (tinnitus, headache, nausea, visual disturbance), hypoglycaemia, QT prolongation. Narrow therapeutic index.
- Suitability: ++++ — still usable orally, but tolerability is poor.
- Used as an alternative when artemisinin combinations aren't available.
2. Artemisinin / SIP Combination (Artesunate-Sulfadoxine-Pyrimethamine)
- Artemisinin derivatives rapidly reduce parasite biomass; the partner drug (SIP) eliminates residual parasites.
- Efficacy: +++++ — Artemisinin-based combinations (ACTs) are the WHO first-line treatment for chloroquine-resistant P. falciparum.
- Safety: +++ — Generally well tolerated; SIP can rarely cause severe skin reactions (Stevens-Johnson).
- Suitability: ++++ — Oral, widely available, affordable.
3. Atovaquone–Proguanil (Malarone)
- Atovaquone inhibits mitochondrial electron transport; proguanil inhibits dihydrofolate reductase.
- Efficacy: ++++ — Effective against resistant P. falciparum.
- Safety: ++++ — Very well tolerated; GI side effects (nausea, vomiting) are the main issue.
- Suitability: ++++ — Oral, once daily dosing, but expensive.
4. Artemisinin / Lumefantrine (Coartem) — Best P-drug for this patient
- Lumefantrine inhibits haem detoxification; combined with artemisinin it provides rapid action + sustained clearance.
- Efficacy: +++++ — WHO first-line ACT; highest efficacy against P. falciparum.
- Safety: +++ — Well tolerated; occasional QT prolongation (less than quinine).
- Suitability: ++++ — Oral, fixed-dose combination (4 tablets twice daily × 3 days), widely available in India.
5. IM Artesunate
- Artesunate is a water-soluble artemisinin derivative; given intramuscularly (or IV).
- Efficacy: ++++ — Excellent; WHO first-line for severe malaria.
- Safety: +++++ — Very safe; mild post-treatment haemolysis is a rare concern.
- Suitability: +++ — Requires parenteral administration; not ideal for uncomplicated disease; reserved for severe/complicated cases or when oral route is unavailable.
Recommended P-drug for Mr. Pawar
Artemisinin / Lumefantrine (Coartem) is the best choice because:
- He has uncomplicated (not severe) chloroquine-resistant P. falciparum malaria — oral therapy is appropriate.
- It has the highest combined efficacy + safety + suitability score.
- WHO and Indian national guidelines recommend ACTs (specifically artemether-lumefantrine) as first-line for chloroquine-resistant P. falciparum.
- He can take it orally, compliance is good (3-day course), and it is available in India.
IM Artesunate would be reserved if he had severe malaria (cerebral malaria, severe anaemia, organ involvement), which is not clearly indicated here.
Sources: Goldman-Cecil Medicine; Katzung's Basic and Clinical Pharmacology, 16th Ed.; Tintinalli's Emergency Medicine
This is a shared conversation. Sign in to Orris to start your own chat.